InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.01%
)
US TECH 100
19,324.00
(
0.38%
)
Dow Jones
42,196.52
(
0.09%
)
Brent Oil
74.78
(
0.22%
)
Bitcoin
61,117.85
(
0.81%
)
Post# of 253268
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Rocky3

Send PM Follow Ignore
Followers 22
Posts 883
Boards Moderated 0
Alias Born 07/31/2010

Rocky3

Re: Rocky3 post# 199336

Thursday, 04/28/2016 8:23:40 AM

Thursday, April 28, 2016 8:23:40 AM

Post# of 253268

I'm expecting BMY WW HCV sales to be larger than ABBV, mainly due to Japan, but that is just a quess.



So, I was a quarter early. BMY had $427MM HCV revenue in 1Q16 ($264MM in US) vs $414MM for ABBV. Japan may take off for ABBV in Q2, but ABBV will continue to see still lower US sales. BMY has steady US sales, dropping Japanese sales, and Australia coming on board (where ABBV is not approved). Plus we now have MRK sales (as meager as they will be for awhile).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up